You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Gilead Sciences to Present at the NASDAQ 20th Investor Program on Thursday, December 6
Gilead Sciences to Present at the 19th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27
Gilead Submits New Drug Application to U.S. FDA for Aztreonam Lysine for Inhalation for Cystic Fibrosis
Gilead Sciences to Present at the 2007 Credit Suisse Healthcare Conference on Wednesday, November 14
Gilead and LG Life Sciences Announce Global License Agreement to Advance Novel Drug Candidates for Treatment of Fibrotic Diseases
Gilead Announces Phase I Data for GS 9190, An Investigational Compound for the Treatment of Chronic Hepatitis C
Gilead Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viread(R) For the Treatment of Chronic Hepatitis B
Gilead Sciences to Present at Two Upcoming Investor Conferences
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan
Gilead Announces New Letairis(TM) (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
Gilead Announces Share Repurchase Program
Caroline Dorsa to Join Gilead as Senior Vice President and Chief Financial Officer
Gilead Sciences Announces Third Quarter 2007 Financial Results
European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Gilead Submits Marketing Applications in the United States and European Union for Viread(R) (Tenofovir Disoproxil Fumarate) for the Treatment of Chronic Hepatitis B
Gilead Sciences to Release Third Quarter 2007 Financial Results on Thursday, October 18, 2007
Gilead Announces Detailed Results of Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Data from Phase II Study of Gilead's Darusentan in Resistant Hypertension Published in Journal of Clinical Hypertension
Gilead Sciences to Present at the 2007 UBS Global Life Sciences Conference on Tuesday, September 25
Gilead Sciences to Present at the Bear Stearns 20th Annual Healthcare Conference on Tuesday, September 11
Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates for Pulmonary Disease
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney
Gilead Sciences Announces Second Quarter 2007 Financial Results
Gilead Sciences to Release Second Quarter 2007 Financial Results on Thursday, July 19, 2007
Gilead Announces Expanded Access Program for Aztreonam Lysine for Inhalation for Patients with Cystic Fibrosis
Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
Gilead Sciences Completes $1 Billion Stock Repurchase Program
Gilead Sciences to Host Conference Call to Discuss the U.S. Food and Drug Administration Approval of Letairis(TM)
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
Gilead Sciences to Present at the Goldman Sachs 28th Annual Healthcare Conference on Wednesday, June 13
Gilead Sciences' Executive Vice President, Commercial Operations Establishes Rule 10b5-1 Stock Trading Plan
Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Gilead Sciences to Present at Bank of America's 2007 Healthcare Conference on Wednesday, May 30
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
Gilead Sciences' Chief Operating Officer and Chief Financial Officer Establishes Rule 10b5-1 Stock Trading Plan
Gilead Sciences to Present at Citigroup's 2007 Global Healthcare Conference on Wednesday, May 23
Gilead Sciences Announces Senior Management Promotion
Gilead Board of Directors Approves Two-for-One Stock Split
Gilead Sciences to Present at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, May 2
Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
Gilead Sciences Announces First Quarter 2007 Financial Results
Gilead Sciences to Release First Quarter 2007 Financial Results on Wednesday, April 18, 2007
Gilead Sciences to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Thursday, April 12
Marketing Authorisation Application for Ambrisentan Validated by European Medicines Agency
Gilead Sciences to Present at the Lehman Brothers 10th Annual Global Healthcare Conference on Monday, March 19
Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
Gilead Sciences Announces New Appointments within Executive Team
Gilead Sciences to Present at the Cowen & Company 27th Annual Health Care Conference on Monday, March 12
Gilead Announces 24-Week Results from Phase II Study of Investigational HIV Integrase Inhibitor GS 9137
Gilead Announces Completion of Phase II Clinical Trial of Novel Investigational HIV Integrase Inhibitor GS 9137
Gilead's New Drug Application for Ambrisentan Receives Priority Review Status
Gilead and Achillion Announce Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Development
Gilead Sciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Wednesday, February 7
Gilead Sciences Announces Fourth Quarter and Full Year 2006 Financial Results
Gilead Sciences to Release Fourth Quarter and Year End 2006 Financial Results on Wednesday, January 31, 2007
Carla A. Hills Joins Gilead Sciences' Board of Directors
Gilead Sciences to Present at the 25th Annual JPMorgan Healthcare Conference on Monday, January 8th
2012 Interactive Annual Report